<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00014664</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068585</org_study_id>
    <secondary_id>PDL-1D10-901</secondary_id>
    <secondary_id>CUMC-0101-552</secondary_id>
    <nct_id>NCT00014664</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma</brief_title>
  <official_title>A Phase II, Open-Label, Randomized, Multicenter Trial To Evaluate The Preliminary Safety And Efficacy of Hu1D10 In Patients With Relapsed Or Refractory Grades I, II, or III B-Cell Non-Hodgkin's Lymphoma (Including Follicular, Small Lymphocytic And Marginal Zone/MALT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PDL BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver&#xD;
      cancer-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of two different monoclonal&#xD;
      antibody regimens in treating patients who have relapsed or refractory non-Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the relative safety of 3 different regimens of monoclonal antibody Hu1D10 in&#xD;
           patients with relapsed or refractory grade I, II, or III B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
        -  Compare the preliminary tumor response and progression-free survival of patients treated&#xD;
           with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive monoclonal antibody (MOAB) Hu1D10 IV over approximately 2 hours&#xD;
           on days 1, 8, 15, and 22.&#xD;
&#xD;
        -  Arm II: Patients receive MOAB Hu1D10 as in arm I at a higher dose.&#xD;
&#xD;
        -  Arm III:Patients receive MOAB Hu1D10 IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24,&#xD;
           and 26.&#xD;
&#xD;
      Treatment in all arms continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed at weeks 1, 4, and 12 and then at months 6, 9, 12, 18, and 24.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2000</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>apolizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed relapsed or refractory grade I, II, or III non-Hodgkin's&#xD;
             lymphoma (NHL), including follicular, small lymphocytic, or marginal zone/MALT&#xD;
             lymphoma&#xD;
&#xD;
          -  Previously treated with radiotherapy, immunotherapy, and/or chemotherapy for NHL&#xD;
&#xD;
               -  Progression of disease or no response since last treatment for NHL&#xD;
&#xD;
          -  1D10+ lymphoma by immunohistochemistry or flow cytometry&#xD;
&#xD;
          -  Bidimensionally measurable disease at least 2 cm in a single dimension&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
          -  Circulating tumor cells no greater than 5,000/mm^3&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3 (unless disease related)&#xD;
&#xD;
          -  Neutrophil count at least 1,000/mm^3 (unless disease related)&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.5 mg/dL&#xD;
&#xD;
          -  SGOT less than 4 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiac disease (New York Heart Association class III or IV)&#xD;
&#xD;
          -  No evidence of myocardial infarction or cardiac arrhythmia (unless surgically&#xD;
             repaired) within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No clinically significant pulmonary disease&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other malignancy within the past 2 years except non-melanoma skin cancer or&#xD;
             carcinoma in situ&#xD;
&#xD;
          -  No significant psychiatric or CNS impairment&#xD;
&#xD;
          -  No active serious infection&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 1 month after study&#xD;
&#xD;
          -  Negative anti-Hu1D10 antibody response (HAHA/HAMA)&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior interferon therapy&#xD;
&#xD;
          -  At least 3 months since prior immunotherapy&#xD;
&#xD;
          -  No prior monoclonal antibody Hu1D10&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior corticosteroids (more than 10 mg prednisone/day)&#xD;
&#xD;
          -  No concurrent corticosteroids at more than 10 mg prednisone/day for pre-existing&#xD;
             diseases or adverse reactions&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior external beam radiotherapy&#xD;
&#xD;
          -  At least 3 months since prior radioimmunotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent lymphoma therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tillman Pearce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Facet Biotech</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Protein Design Labs, Inc.</name>
      <address>
        <city>Freemont</city>
        <state>California</state>
        <zip>94555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2002</verification_date>
  <study_first_submitted>April 10, 2001</study_first_submitted>
  <study_first_submitted_qc>June 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2003</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

